Instruction 1(b).

longer subject to Section 16. Form 4 or Form 5 obligations $\ \, \text{may continue.} \, \textit{See}$

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL						
OMB Number: 3235-02						
Estimated average burden						
hours per response	0.5					

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	be Responses	7													
1. Name and Address of Reporting Person *- Haqq Christopher			2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) 3260 BAYSHORE BOULEVARD				3. Date of Earliest Transaction (Month/Day/Year) 10/15/2014						X_Officer (give title below) Other (specify below) Chief Medical Officer					
(Street) BRISBANE, CA 94005				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)			Table I - Non-Derivative Securities Acqu						Acquired,	lired, Disposed of, or Beneficially Owned					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year			2A. Deemed Execution Date, if			f Code (A) (Inst		or Disposed of (D) Over Str. 3, 4 and 5)		5. Amount of Securities B Owned Following Report Transaction(s) (Instr. 3 and 4)		ed (Ownership of Form: B	Nature f Indirect eneficial wnership nstr. 4)	
Reminder: F	Report on a se	eparate line for eac		Derivative	Seci	urities A	cqui	Persons containe form disp	who respond in this forrolays a curre	m are not i ently valid ficially Ow	required OMB co	to respon	nd unless th		74 (9-02)
1. Title of Derivative Security		se (Month/Day/Year) any (Month/Day/		4. Transaction Code (Instr. 8)		5. Number		Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	f 10. Ownership	11. Natur
(Instr. 3)	Price of Derivative Security		(Month/Day/Year	(Instr. 8)		Acquired (A) or Disposed (D) (Instr. 3,	d d of		/ I cal)	Securities		-	Securities Beneficially Owned Following Reported Transaction(Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
(Instr. 3)	Derivative		, ,	(Instr. 8)		Acquired (A) or Disposed (D) (Instr. 3,	d d of	Date Exercisable	Expiration	Securities		-	Securities Beneficially Owned Following Reported Transaction(Form of Derivative Security: Direct (D) or Indirect (S) (I)	Ownersh (Instr. 4)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Haqq Christopher 3260 BAYSHORE BOULEVARD BRISBANE, CA 94005			Chief Medical Officer			

Signatures

/s/ Tina Gullotta, Attorney-in-Fact for Christopher Haqq	10/16/2014	
Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.